In India, the phytopharmaceuticals (derived from plants in which minimum four analytical/biomarkers must be characterized) shall be considered and approved as a drug as per the amendment in Drugs & Cosmetics rule 1945. Besides characterizing four markers, other regulatory requirements also shall be complied by the marketing authorization holders.

I request, the colleagues can elaborate whether in your respective country such provisions are being made?